Maja V. Malakhova

Maja V. Malakhova

Auto-generated profile, based on publicly available information

Maja V. Malakhova

Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in Bulletin of Russian State Medical University
Verified
Journal Article
Closed access
NKNs Kuptsov
Ns Kuptsov
MKMaria Kornienko
Maria Kornienko
RGRoman Borisovitch Gorodnichev
Roman Borisovitch Gorodnichev
DDDI Danilov
DI Danilov
MMMv Malakhova
Mv Malakhova
EIEn Ilina
En Ilina
The ever-rising prevalence of multidrug-resistant bacteria necessitates the search for a therapeutic alternative to antibiotics. Using therapeutic products based on virulent bacteriophages might provide such an alternative. The aim of our study was to evaluate the efficacy of commercial phage products and natural bacteriophage monoisolates recovered from environmental sources against clinical strains of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa. We compiled a collection of 147 strains that were subsequently genotypes using the MLST method. The efficacy of bacteriophages was evaluated in spot tests. The highest efficacy was demonstrated by "Staphylococcal bacteriophage" (86%, effective against S. aureus), "Purified polyvalent pyobacteriophage" (87.8%, effective against K. pneumoniae), and a group of phage products against P. aeruginosa, including "Pseudomonas aeruginosa bacteriophage" (87.5%), "Complex pyobacteriophage" (79.5–90%) and "Purified polyvalent pyobacteriophage" (90–92.5%). The efficacy of "Intesti bacteriophage", which targets E. faecium, was 4.2%. The efficacy of commercial phage products against S. aureus and K. pneumoniae was higher than the efficacy of individual phage monoisolates (60% for the S. aureus phage vB_SauP-436-3w and 5.9% for the K. pneumoniae phage vB_Kp_M_ Seu621). Thus, all tested commercial phage products were highly effective against P. aeruginosa, K. pneumoniae and S. aureus. There are no commercial phage products on the market against other ESKAPE pathogens, including Acinetobacter baumannii and Enterobacter cloacae. Besides, there are no effective phage products against E. faecium. This dictates the need for new effective bacteriophages against these species.

1 January 2022 in Molecular Genetics Microbiology and Virology (Russian version)
Verified
Journal Article
Closed access
TST.V. Solomay
T.V. Solomay
MMM.V. Malakhova
M.V. Malakhova
ESEgor Shitikov
Egor Shitikov
DBDmitry Bespiatykh
Dmitry Bespiatykh
VVVladimir Alexandrovich Veselovsky
Vladimir Alexandrovich Veselovsky
EFE.B. Fayzuloev
E.B. Fayzuloev
Вирусом Эпштейна—Барр (ВЭБ) инфицировано около 90% населения планеты. Ущерб здоровью и высокие экономические потери требуют разработки вакцин против ВЭБ-инфекции. Вариабельность отдельных генов может повлиять на успех прививочной кампании и будет требовать динамического обновления антигенного состава вакцин. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка вариабельности генов gp350 и EBNA2 ВЭБ, выделенного из слюны персонала стоматологических клиник московского региона. МАТЕРИАЛ И МЕТОДЫ Биологические образцы (слюна) получены от 105 сотрудников четырех стоматологических клиник. Для образцов, содержащих ДНК ВЭБ, проводили амплификацию генов gp350 и EBNA2 методом нестед-ПЦР. Определение нуклеотидной последовательности гена gp350 осуществляли в ходе секвенирования. Построение филогенетического дерева максимального правдоподобия проводили по N-концевому фрагменту белка gp350, в качестве референсного генома использовали последовательность штамма B95-8. В филогенетический анализ дополнительно включены 222 образца ВЭБ из базы данных NCBI. РЕЗУЛЬТАТЫ Генотип по EBNA2 и полная последовательность гена gp350 были определены для 31 образца ДНК. Согласно филогенетическому анализу N-концевой последовательности белка gp350 исследуемых образцов и образцов из базы данных NCBI, представители российской популяции вируса были равномерно распределены по дереву. При этом 30 образцов относились к кладе Aa (A — генотип A по гену EBNA2; a — схожесть последовательности gp350 с B95-8 (NC_007605.1)), один — к кладе Bb (B — генотип B по гену EBNA2; b — схожесть gp350 с таковым у Jijoye (LN827800.1)). Для 30 российских образцов генотипа Aa было обнаружено 22 индивидуальных профиля и 16 уникальных мутаций. Среди персонала, работающего в тесном профессиональном контакте, обнаружены идентичные профили gp350. ЗАКЛЮЧЕНИЕ Выявленные особенности указывают на необходимость проведения дальнейшего филогенетического исследования образцов, отобранных на территории России, для разработки и внедрения вакцин и мониторинга их эффективности.

30 March 2026 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
MZMarina Zaychikova
Marina Zaychikova
VAVadim Vadimovich Avdeev
Vadim Vadimovich Avdeev
SKSofya Kuznetsova
Sofya Kuznetsova
MMMaja V. Malakhova
Maja V. Malakhova
ESEgor Shitikov
Egor Shitikov
МВМалахова Майя Владимировна
Малахова Майя Владимировна
Mycobacteriophages are viruses that selectively infect mycobacteria. Due to their specificity and lytic activity, they are considered a promising tool for controlling mycobacterial infections, especially amid rising antibiotic resistance. Their significant genetic diversity and unique biological properties have generated sustained global research interest, supported by successes in treating complex infections caused by non-tuberculous mycobacteria. However, data on phage populations and applied research results in the Russian Federation remain fragmented, necessitating systematization to assess the genuine potential. This review is based on literature data and the authors’ personal results, summarizing current knowledge on mycobacteriophage biology and analyzing the prospects for their therapeutic and diagnostic application. It examines data on mycobacteriophage taxonomic and genomic diversity in a global context, describes the first characterized Russian isolates, including phages Vic9 and Yasnaya_Polyana, and details a domestic collection of 15 phages. The collection aligns with global trends and includes unique findings, such as the phage Arbat with an anomalously large genome and extremely low similarity to known phages. In the therapy context, the review explores strategies for creating effective therapeutic agents, including the design of phage cocktails and genetic modification to switch them to a lytic state. It presents a critical analysis of international clinical experience using phages in parallel with mycobacterioses and highlights fundamental barriers to phage therapy for tuberculosis. Special attention is paid to domestic delivery systems, particularly liposomal formulations of phage D29, which have demonstrated high efficacy against M. tuberculosis, including multidrug-resistant strains, and a favorable safety profile in preclinical studies. In the diagnostics section, the evolution of phage-based methods is traced — from biological amplification tests to reporter systems — and the Russian-developed test system “TB-Phage-LCh” for phenotypic tuberculosis drug susceptibility testing is presented. Despite regulatory complexities and the need to study immunogenicity, this work demonstrates that Russian Federation possesses a solid scientific foundation for developing this field. Further research focused on in-depth characterization of domestic isolates, optimization of therapeutic platforms, and conducting controlled clinical trials could lead to creating effective phage-based drugs and diagnostic tools capable of holding an important place in the arsenal against drug-resistant mycobacterial infections.

24 November 2024 in Extreme Medicine
Verified
Journal Article
Open access
PDF file
AKA. O. Krivulia
A. O. Krivulia
RGRoman Borisovitch Gorodnichev
Roman Borisovitch Gorodnichev
MKMaria Kornienko
Maria Kornienko
NANarina Kazbekovna Abdraimova
Narina Kazbekovna Abdraimova
MMM. V. Malakhova
M. V. Malakhova
ESEgor Shitikov
Egor Shitikov
Introduction. Klebsiella pneumoniae poses a serious threat to global healthcare due to the high proportion of multidrug-resistant isolates. Moreover, the formation of biofilms by bacteria significantly complicates the treatment of infections.Objective. To evaluate the effectiveness of the individual and combined action of antibiotics and bacteriophages or polysaccharide depolymerase on biofilms of a clinically significant strain K. pneumoniae.Materials and methods. The work used the K. pneumoniae strain with multidrug resistance (9faiz), 4 antibiotics of various classes (gentamicin, levofloxacin, meropenem and chloramphenicol), 3 bacteriophages of various genera (Dlv622, Seu621 and FRZ284), and 1 polysaccharide depolymerase (Dep622). Experiments were carried out on the formed biofilms by treating 24-hour K. pneumoniae films with antimicrobial agents individually or in combinations. The ability of the strain to form biofilms was evaluated by staining with crystalline violet. The comparison between the average optical density values was carried out using a t-test and was considered significant at p ≤ 0.05.Results. The individual use of antibiotics peak concentrations (Cmax) or depolymerase concentration of 100 MED (minimum effective dose — MED) did not lead to a significant decrease in biofilm biomass, whereas bacteriophages in a titer of 5×109 PFU/mL (plaque-forming unit per mL) statistically significantly reduced its biomass by 27–31% (p < 0.05) Most combinations of phages and antibiotics did not lead to a significant increase in the efficiency of biofilm destruction. Only the combination of phage FRZ284 with gentamicin statistically significantly showed an additional decrease in biofilm biomass by 27% (p < 0.05).Conclusions. The results show the need for individual selection of antimicrobial combinations to combat K. pneumoniae biofilms due to the possible effect of synergy and antagonism effects on the outcome of therapy.

1 September 2022 in Molecular Genetics, Microbiology and Virology
Verified
Journal Article
Closed access
PDF file
TST. V. Solomai
T. V. Solomai
MMM. V. Malakhova
M. V. Malakhova
ESEgor Shitikov
Egor Shitikov
DBD. A. Bespyatykh
D. A. Bespyatykh
VVV. A. Veselovskii
V. A. Veselovskii
EFEvgeny Faizuloev
Evgeny Faizuloev
Approximately 90% of the world’s population is infected with the Epstein–Barr virus (EBV). Damage to health and high economical costs require t